Glen­mark to com­mer­cialise Ryal­tris in Aus­tralia, NZ

BioSpectrum (Asia) - - Company News -

Glen­mark Pharma’s sub­sidiary Glen­mark Spe­cialty has en­tered into an ex­clu­sive li­cens­ing agree­ment with Aus­tralia’s Se­qirus to com­mer­cialise its nasal spray Ryal­tris in Aus­tralia and New Zealand. Ryal­tris is in­di­cated for treat­ment of symp­toms as­so­ci­ated with sea­sonal al­ler­gic rhini­tis (SAR) in pa­tients over 12 years of age. Un­der the terms of the agree­ment, Glen­mark will be re­spon­si­ble for prod­uct sup­ply and Se­qirus will be re­spon­si­ble for reg­u­la­tory fil­ing and com­mer­cial­i­sa­tion of the prod­uct in Aus­tralia and New Zealand. Glen­mark will re­ceive an up­front pay­ment as well as reg­u­la­tory and com­mer­cial mile­stone pay­ments from Se­qirus. In

May 2018, Glen­mark filed a New Drug Ap­pli­ca­tion (NDA) for Ryal­tris with the US Food and Drug Ad­min­is­tra­tion (USFDA). The com­pany plans to com­mer­cialise Ryal­tris in sev­eral key mar­kets glob­ally.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.